Dianthus Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2019
Filed with the SEC on Mar 3, 2020 and accepted by EDGAR at Mar 3, 2020, 08:21 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-10-01 to 2019-12-31 | $0 | us-gaap:Revenues |
| Revenue | 12 months2019-01-01 to 2019-12-31 | $0 | us-gaap:Revenues |
| Research and development | 12 months2019-01-01 to 2019-12-31 | $59.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-10-01 to 2019-12-31 | −$24.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2019-01-01 to 2019-12-31 | −$83.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2019-01-01 to 2019-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-10-01 to 2019-12-31 | −$23.2m | us-gaap:NetIncomeLoss |
| Net income | 12 months2019-01-01 to 2019-12-31 | −$76.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-10-01 to 2019-12-31 | −$0.59 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 12 months2019-01-01 to 2019-12-31 | −$2.07 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2019-01-01 to 2019-12-31 | −$57.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2019-01-01 to 2019-12-31 | $3.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-12-31 | $65.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-12-31 | $149.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-12-31 | $161.5m | us-gaap:Assets |
| Current liabilities | At period end2019-12-31 | $14.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-12-31 | $20.3m | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-12-31 | $141.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001193125-20-059835. Last ingested by Listed: Nov 10, 2026, 03:21 ET. Listed shows no prices and gives no investment advice.